TIDMAVCT

Avacta Group PLC

19 July 2016

Hardman report: New Affimer development opportunities

Hardman & Co research report: New Affimer development opportunities

Avacta is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group's Affimer technology is a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. While Avacta has made considerable progress towards developing its own bio-therapeutics in 2016, two announcements recently have expanded its Affimer technology into new areas with large commercial potential. There remains a clear mismatch between the current EV and the long-term potential of Affimers.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/avacta-documents/18-07-16-new-affimer-development-opportunities

 
 To contact us:      Contact: Dr Martin Hall 
  Hardman & Co        mh@hardmanandco.com 
  11/12 Tokenhouse    Dr Gregoire Pave 
  Yard                gp@hardmanandco.com 
  London              Telephone: +44 20 7929 3399 
  EC2R 7AS            Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAKMGMNVRGGVZM

(END) Dow Jones Newswires

July 19, 2016 02:15 ET (06:15 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avacta Charts.